Posaconazole tablets, a new oral formulation of posaconazole, can be effective when given as antifungal prophylaxis to neutropenic patients at high risk for invasive fungal infection (e.g., those with acute myelogenous leukemia or myelodysplastic syndrome). Such effectiveness might be specifically important to patients with poor oral intake because of nausea, vomiting, or chemotherapy-associated mucositis. This was a prospective, global study in high-risk patients to characterize the pharmacokinetics and safety profile of posaconazole tablets and to identify the dose of posaconazole tablets that would provide exposure within a predefined range of exposures (steady-state average concentration [area under the concentration-time curve/24 h] of >500 ng/ml and <2,500 ng/ml in >90% of patients). The study evaluated two sequential dosing cohorts: 200 mg posaconazole once daily (n ؍ 20) and 300 mg posaconazole once daily (n ؍ 34) (both cohorts had a twice-daily loading dose on day 1) taken without regard to food intake during the neutropenic period for <28 days. The current commercial formulation, posaconazole oral suspension, has been effective and generally well tolerated as IFI prophylaxis when given to neutropenic patients after chemotherapy for AML or MDS. Previously, in a large, global, phase 3 controlled clinical trial of such patients, treatment with 200 mg posaconazole oral suspension three times daily resulted in fewer proven or probable IFIs (2% versus 8%; P Ͻ 0.001), lower incidences of invasive aspergillosis (1% versus 7%; P Ͻ 0.001), and prolonged survival (P ϭ 0.04) than treatment with itraconazole or fluconazole (1). In a similar controlled study in immunosuppressed patients with graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation, compared with fluconazole, posaconazole oral suspension effectively prevented invasive mold infections and reduced the related mortality rate (2).Despite its effectiveness in the registration trials, the posaconazole oral suspension has practical limitations: it must be administered multiple times daily and must be taken with food (high-fat diet preferred) so that adequate systemic exposure can be achieved (3, 4). These limitations are particularly important in hematology patients eligible for antifungal prophylaxis, in whom chemotherapy-induced adverse effects, including severe nausea or vomiting, mucositis, and diarrhea, often make it difficult to ensure adequate food intake to optimize exposure of the posaconazole oral suspension (5-7). Until now, absorption could be enhanced in these patients if posaconazole doses were divided (200 mg four times daily) or if the drug was administered with a liquid nutritional supplement or an acidic drink such as ginger ale (4,8). Even with these measures, target exposures in many patients could not be achieved; 25% of patients with neutropenia achieved steady-state plasma concentrations of Ͻ322 ng/ml when taking the recommended 200-mg dose of the posaconazole oral suspension three times a day for antifungal ...